Related Experiment Video
Updated: May 31, 2025
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
Published on: September 15, 2018
Extracellular vesicular microRNAs and cardiac hypertrophy
Hai Hu1,2, Xiulian Wang1, Hui Yu1,2
1Inner Mongolia Key Laboratory of Disease-Related Biomarkers, The Second Affiliated Hospital, Baotou Medical College, Baotou, China.
Insights
Extracellular vesicle-derived microRNAs (miRNAs) are key players in cardiac hypertrophy, a condition leading to heart failure. Understanding these miRNAs offers potential diagnostic and therapeutic strategies for heart disease.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Extracellular Vesicle Research
Background:
- Cardiac hypertrophy is a response to heart overload, often leading to heart failure.
- Its progression involves complex cellular and molecular changes.
- Identifying inhibitory molecular mechanisms is crucial for new therapies.
Purpose of the Study:
- To review recent advancements in extracellular vesicle (EV) research.
- To highlight the role of EV-derived microRNAs (miRNAs) in cardiac hypertrophy.
- To discuss the diagnostic and therapeutic potential of EV-derived miRNAs.
Main Methods:
- Review of current literature on extracellular vesicles and cardiac hypertrophy.
- Analysis of EV biogenesis, cargoes, and miRNA functions.
- Examination of regulatory mechanisms of EV-derived miRNAs.
Main Results:
- EVs and their miRNA cargo are significantly involved in cardiac hypertrophy development.
- EV-derived miRNAs exhibit specific functions and regulatory roles in this condition.
- Recent findings illuminate the complex interplay between EVs, miRNAs, and cardiac remodeling.
Conclusions:
- EV-derived miRNAs are critical mediators in cardiac hypertrophy.
- These miRNAs hold promise as biomarkers for diagnosis.
- Targeting EV-derived miRNAs presents a novel therapeutic avenue for heart failure.
Abstract:
Cardiac hypertrophy is an adaptive response to pressure or volume overload such as hypertension and ischemic heart diseases. Sustained cardiac hypertrophy eventually leads to heart failure. The pathophysiological alterations of hypertrophy are complex, involving both cellular and molecular systems. Understanding the molecular events that inhibit or repress cardiac hypertrophy may help identify novel therapeutic strategies. Increasing evidence has indicated that extracellular vesicle (EV)-derived microRNAs (miRNAs) play a significant role in the development and progression of cardiac hypertrophy. In this review, we briefly review recent advancements in EV research, especially on biogenesis, cargoes and its role in cardiac hypertrophy. We then describe the latest findings regarding EV-derived miRNAs, highlighting their functions and regulatory mechanisms in cardiac hypertrophy. Finally, the potential role of EV-derived miRNAs as targets in the diagnosis and treatment of cardiac hypertrophy will be discussed.
